Overview

A Prospective Randomized Double-Blind Trial Comparing 3 Doses of Intravenous Ketorolac for Pain Management

Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
Hypothesis: Intravenous administration of Ketorolac in a dose of 10 mg is as effective in treating severe acute pain in patients presenting to the ED as 15 mg and 30 mg.
Phase:
Phase 4
Details
Lead Sponsor:
Antonios Likourezos
Treatments:
Ketorolac
Ketorolac Tromethamine